Atlas Capital Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Atlas Capital Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.25K	Hold	138	–	–	﹤0.01%	879
2025 Q4	$2.31K	Buy	+138	New	+$2.32K	﹤0.01%	842
2025 Q2	$1.77K	Hold	138	–	–	﹤0.01%	867
2025 Q1	$1.75K	Hold	138	–	–	﹤0.01%	909
2024 Q4	$1.81K	Buy	+138	New	+$1.99K	﹤0.01%	873
2024 Q3	–	Sell	-138	Closed	-$1.96K	–	934
2024 Q2	$1.96K	Buy	+138	New	+$1.87K	﹤0.01%	828
2024 Q1	–	Sell	-138	Closed	-$1.86K	–	927
2023 Q4	$1.86K	Hold	138	–	–	﹤0.01%	833
2023 Q3	$1.72K	Hold	138	–	–	﹤0.01%	814
2023 Q2	$1.87K	Hold	138	–	–	﹤0.01%	826
2023 Q1	$1.92K	Hold	138	–	–	﹤0.01%	836
2022 Q4	$1.96K	Hold	138	–	–	﹤0.01%	832
2022 Q3	$1.89K	Hold	138	–	–	﹤0.01%	837
2022 Q2	$1.96K	Buy	+138	New	+$2.08K	﹤0.01%	909

Other funds holding HQL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Atlas Capital Advisors's HQL Position: Q1 2026 in Review

Atlas Capital Advisors held its abrdn Life Sciences Investors (HQL) position steady in Q1 2026 at 138 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #879.

Atlas Capital Advisors first reported a position in HQL in Q2 2022 and has held it in 13 quarters since. The position peaked at $2.31K in Q4 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

Atlas Capital Advisors held 138 shares of abrdn Life Sciences Investors worth $2.25K as of Q1 2026.
Atlas Capital Advisors left its abrdn Life Sciences Investors share count unchanged in Q1 2026.
abrdn Life Sciences Investors made up ﹤0.01% of Atlas Capital Advisors's portfolio in Q1 2026, its #879 holding.
Atlas Capital Advisors first reported a position in abrdn Life Sciences Investors in Q2 2022 and has held it in 13 quarters since.
Atlas Capital Advisors's abrdn Life Sciences Investors position peaked at $2.31K in Q4 2025.
86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.